AIM ImmunoTech Inc. - AIM STOCK NEWS

AIM ImmunoTech Inc. has announced the advancement of its Phase 2 study for Ampligen, targeting post-COVID conditions. Following the FDA's approval of its IND application, the enrollment for the study is set to begin in Q1 2023. This randomized, double-blind, placebo-controlled trial will evaluate the safety and efficacy of Ampligen in around 80 patients suffering from fatigue related to post-COVID conditions. Initial findings from previous studies indicate potential therapeutic benefits, highlighting the urgency to address this growing public health issue.

AIM ImmunoTech has received FDA clearance to initiate a Phase 2 study for its drug, Ampligen, targeting post-COVID conditions. The trial, expected to begin enrollment in Q1 2023, will assess the drug's effectiveness in treating symptoms like fatigue and ‘brain fog’. Approximately 80 subjects aged 18-60 will participate in this double-blind, placebo-controlled study. Initial data from previous trials suggests promising safety and efficacy. This trial aims to address significant unmet medical needs for patients suffering from debilitating post-COVID symptoms.

AIM ImmunoTech is set to host a Virtual Investor Long COVID Event on September 28, 2022, at 3:00 PM ET. The event will feature a moderated discussion with Key Opinion Leaders Dr. Charles Lapp and Dr. Daniel Peterson, focusing on the company’s FDA-authorized treatment protocol for its investigational drug, Ampligen, aimed at patients with long COVID symptoms. Investors can submit questions live during the event, and a replay will be available shortly after.

AIM ImmunoTech Inc. has made significant strides in repurposing its lead drug, Ampligen, for oncology treatments, especially over the past 18 months. The company filed its Definitive Proxy Statement ahead of its Annual Meeting on November 3, 2022, urging shareholders to support its current board against the Jorgl Activist Group. Highlights include positive interim trial results and FDA approval to proceed with a Phase 2 study for Ampligen in pancreatic cancer. AIM holds approximately $41.7 million in liquid assets, ensuring financial stability through 2023.

AIM ImmunoTech Inc. (AIM) announced that CEO Thomas K. Equels will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York and virtually from September 12-14, 2022. The event emphasizes AIM's commitment to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Attendees can engage in one-on-one meetings with management. A video webcast of the presentation will be available starting September 12 at 7:00 AM ET and archived for 90 days.

AIM ImmunoTech announced that Chris McAleer, Ph.D., and William Mitchell, M.D., Ph.D., will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care, held from September 8-10, 2022, at Roswell Park Comprehensive Cancer Center, Buffalo, N.Y. The presentations focus on Rintatolimod as an investigational immunomodulatory agent targeting cancers with high unmet need. AIM is sponsoring the event, and details will be available on their website post-presentation.

AIM ImmunoTech Inc. (AIM) announced the commencement of patient enrollment in a Phase 2 clinical trial funded by the National Cancer Institute. The trial evaluates the combination of a type-1 polarized dendritic cell vaccine with Interferon alpha-2b, Ampligen, and Celecoxib for HLA-A2+ refractory melanoma patients. First patient dosing is expected in Q4 2022. The study aims to enroll up to 24 participants, assessing objective response rates and efficacy. AIM's CEO views this as a significant milestone in developing second-line therapies for patients resistant to PD-1/PD-L1 treatment.

AIM ImmunoTech (NYSE: AIM) has announced the IRB approval to commence its Phase 2 clinical trial for Ampligen in treating locally advanced pancreatic cancer (LAPC). The trial, AMP-270, aims to evaluate the efficacy of Ampligen against a no-treatment control group following FOLFIRINOX chemotherapy. Approximately 90 subjects will be enrolled across 30 centers in the U.S. and Europe. Initial data from a small cohort showed promising survival rates, with two patients surviving 34 and 43 months, and one patient alive at 54 months. The trial is expected to start patient recruitment by Q4 2022.

AIM ImmunoTech Inc., an immuno-pharma company focused on therapies for cancers and viral diseases, announced that the Delaware Court of Chancery denied an activist shareholder's temporary restraining order aimed at influencing the Board's composition. Jonathan Jorgl sought to nominate candidates for the Board at the 2022 Annual Meeting, but the Court's decision means that AIM can proceed without disruption. A preliminary injunction hearing is scheduled for October 5, 2022. The Company continues its commitment to protect shareholder rights.